| |
| Issue |
Title |
| |
| No 2 (2022) |
Real clinical practice data: comparison of the efficacy and safety of apixaban and rivaroxaban in the treatment of VTE |
Abstract
PDF (Rus)
|
|
article Editorial |
| |
| No 1 (2022) |
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation |
Abstract
PDF (Rus)
|
|
article Editorial |
| |
| No 1 (2022) |
Hyperuricemia from A to Z |
Abstract
PDF (Rus)
|
|
article Editorial |
| |
| No 2 (2020) |
АПИКСАБАН ПРОДЕМОНСТРИРОВАЛ ПРЕВОСХОДСТВО НАД РИВАРОКСАБАНОМ ПРИ ПРИМЕНЕНИИ У ПАЦИЕНТОВ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ |
Abstract
PDF (Rus)
|
|
|
| |
| No 4 (2019) |
UPTRAVI (SELEXIPAG) HAS BEEN REGISTERED IN THE RUSSIAN FEDERATION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN ADULT PATIENTS |
Abstract
PDF (Rus)
PDF (Eng)
|
|
article Editorial |
| |
| No 4 (2019) |
FINDINGS RELEASED FROM NAXOS, A FRENCH REAL-WORLD DATA ANALYSIS AND THE LARGEST REAL-WORLD DATA ANALYSIS ON ORAL ANTICOAGULANT EFFECTIVENESS AND SAFETY IN EUROPE AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION |
Abstract
PDF (Rus)
PDF (Eng)
|
|
article Editorial |
| |
| 1 - 6 of 6 Items |
|
